Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • Daniel Simmonds

  • Drew Meredith

  • Giselle Roux

  • Ishan Dan

  • James Dunn

  • Kanish Chugh

  • Staff Writer

  • Tahn Sharpe

  • The Inside Adviser

Growth managers continue to shine

It’s been a while since “value investing” made sense: the style has suffered a dreadful stretch of performance since the 2008 financial crisis. The ‘Warren Buffett’ mantra of buying low (cheap) and selling high has seen value-oriented managers underperform the market year after year. But that’s not to say value investing is dead, it’s just…

Ishan Dan | 19th Oct 2020 | More
Water utilities – dull but dependable?

I want to discuss a water utility, which may sound as dull as dishwater – but we global real assets investors have never been averse to safe, predictable, and yes, boring companies. The type of company that pays a dividend that is as dependable as a birthday cheque from Grandma. We have specialist in-house capability…

Daniel Simmonds | 15th Oct 2020 | More
Will $5.20 Fill the Missing Link?

Shareholders of Link Administration Holdings (LNK), which provides services to the funds management and superannuation sectors and runs the share registry for many of the S&P/ASX 200 companies, have become the latest group to experience the tailwind that a takeover offer can suddenly blow on to a becalmed share price. Last weekend, a consortium of…

James Dunn | 14th Oct 2020 | More
  • Market update; ASX struggles higher

    ASX struggles higher, rates on hold, giant gold merger, US stocks fall The ASX 200 (ASX:XJO) struggled to a 0.3% gain on Tuesday, the energy, +2.3%, and materials sector, +1.1%, the key contributors. The biggest news was the ‘merger of equals’ between Australian gold miners Saracen Minerals (ASX:SAR) and Northern Star Mining (ASX:NST). The merger…

    Drew Meredith | 6th Oct 2020 | More
    Winning in a “K-Shaped” Recovery

    The S&P 500 Index reached a historic high on February 19th of this year, only to break that record less than six months later. On its face this sounds reasonable, however when considering the unprecedented nature of the events that transpired in-between, this is downright shocking. Over this six-month period the S&P 500 realised its…

    Staff Writer | 28th Sep 2020 | More
    If you can’t beat them, buy them

    While the active versus passive debate rolls on, and on, across the investment world, some active managers have gone to the ‘dark side’, at least partially, by adding more quantitative inputs for new strategies, such as thematic investing. The concept of ‘thematic’ investing, which describes the strategy of identifying sectors of the economy expected to…

    Drew Meredith | 25th Sep 2020 | More
  • ASX update; second wave hits Europe

    Financials, miners hit as the second wave hits Europe, RBA guidance, strong open ahead The ASX 200 (ASX:XJO) fell to a three month low on Tuesday, down 0.7%. The sustained sell off has been driven by signs of a second wave engulfing Europe and the potential for another round of economic restrictions. Materials (-0.2%) was…

    Drew Meredith | 22nd Sep 2020 | More
    ASX shares update; Trump bans WeChat

    ASX 200 ekes out a gain, tech profit taking continues, Trump bans WeChat Global markets continued their negative trend on Friday, the ASX 200 (ASX:XJO) falling 0.3%, but managing to finish the week up a solitary 5 points; outperforming most global markets. It was a similar story in the US, with both the Nasdaq and…

    Drew Meredith | 21st Sep 2020 | More
  • ASX shares update; Trump bans WeChat

    ASX 200 ekes out a gain, tech profit taking continues, Trump bans WeChat Global markets continued their negative trend on Friday, the ASX 200 (ASX:XJO) falling 0.3%, but managing to finish the week up a solitary 5 points; outperforming most global markets. It was a similar story in the US, with both the Nasdaq and…

    The Inside Adviser | 21st Sep 2020 | More
    ASX update; COVID-19 impacting Macquarie Group

    Vaccine trial restart boosts markets, ASX strength to continue, COVID-19 impacting Macquarie Group A positive lead from Wall Street and news that AstraZeneca plc (NYSE:AZN) had resumed their vaccine trial sent the ASX 200 (ASX:XJO) 0.7% higher on Monday. Positive news on the vaccine front support the energy and industrial sectors amid hope of a…

    Drew Meredith | 14th Sep 2020 | More